Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report Abstract #2938

Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).
Aim(s): To report a patient suffered from rectal NET and ECD simultaneously.
Materials and methods: A 44-year-old man, with a 7 years history of rectal NET, complaining that he has had a backache as well as vision and hearing impairment for 2 years. Craniocerebral MRI revealed thickened bilateral choroid plexus and endocranium with multiple nodules. Pelvic MRI identified abnormal signals of lumbar, bilateral pelvis and proximal femurs. Both 18F-FDG-PET/CT and 68Ga-DOTANOC-PET/CT demonstrated high uptake of radiotracers in the region of perirectal lymph nodes while no uptake in the lesions of bones and brain. After multidisciplinary discussion, pelvic bones biopsy was performed to identify the property of lesions. Notably, histology reveled infiltration of abundant foamy histiocytes. Immunohistochemistry confirmed CD68(+), CD163(+), Factor XIII a (+), S-100(-), CD1a (-), Langerin (-). And there was no mutation of BRAF V600E. So, the final diagnosis was ECD. For treatment of ECD, interferon alfa (180µg/week) was applied to the patient. To remove lymph node metastasis of rectal NET, a total mesorectal excision surgery was performed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Jie Chen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2685 Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models
Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Shan Wu
Authors: Wu S, Zhou J, Guo J, Hua Z, ...
#2690 Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report
Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Wang C, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2714 The Clinical Outcome of Non-Curative Resection of Small Rectal Neuroendocrine Tumours
Introduction: Small rectal NETs are thought to be less aggressive and relatively benign. However, lymphovascular invasion(LVI) or positive margin after endoscopic resection(ER) was noticed in small rectal NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Haiyi Hu
Authors: Hu H, Li R, Xu R, Zhang S, ...
#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David C. Metz
Authors: Metz D C, Liu E, Joish V N, Huynh L, ...